Ardena has produced and delivered a new cancer nanomedicine, MBS8, into the clinical phase for its client MonTa Biosciences, in just over a year from end to end. “We set a pretty demanding timeline for our MBS8 cancer immunotherapy candidate drug and Ardena delivered,” said Simon Skjøde Jensen, CEO of MonTa Biosciences. “They fast-tracked it from pre-clinical to the clinical phase seamlessly, which is impressive considering this technology is a new area of nanoparticle-based cancer immunotherapy.”

Read more about this press release: